Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 5/20 | 0.40 |
| ▸ | CDK9 | P50750 | 5/20 | 0.40 |
| ▸ | MGLL | Q99685 | 5/20 | 0.38 |
| ▸ | RBP4 | P02753 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981954 | 0.93 | BTK (0.40) | CCNT1CDK9MGLLRBP4BRD4 | |
| SCHEMBL985719 | 0.93 | EPHX2 (0.40) | CCNT1CDK9MGLLRBP4BRD4 | |
| SCHEMBL982969 | 0.92 | BRD4 (0.39) | CCNT1CDK9MGLLRBP4BRD4 | |
| SCHEMBL981263 | 0.91 | MDM4 (0.37) | CCNT1CDK9KMT2ATBK1MEN1 | |
| SCHEMBL981821 | 0.90 | TBK1 (0.41) | CCNT1CDK9KMT2ATBK1PAK1 | |
| SCHEMBL983050 | 0.89 | BRD4 (0.37) | CCNT1CDK9BRD4KMT2AALDH1A1 | |
| SCHEMBL982027 | 0.89 | BRD4 (0.37) | MGLLRBP4BRD4KMT2AMEN1 | |
| SCHEMBL982137 | 0.89 | MAP3K5 (0.34) | CCNT1CDK9TBK1 | |
| SCHEMBL981788 | 0.88 | BRD4 (0.43) | RBP4BRD4KMT2AMEN1ALDH1A1 | |
| SCHEMBL983530 | 0.88 | BTK (0.40) | CCNT1CDK9MGLLRBP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | CCNT1 807/4885CDK9 639/4885MGLL 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.